GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Evogene Ltd (NAS:EVGN) » Definitions » Float Percentage Of Total Shares Outstanding

Evogene (Evogene) Float Percentage Of Total Shares Outstanding : 99.66% (As of Apr. 29, 2024)


View and export this data going back to 2013. Start your Free Trial

What is Evogene Float Percentage Of Total Shares Outstanding?

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Evogene's float shares is 50.45 Mil. Evogene's total shares outstanding is 50.62 Mil. Evogene's float percentage of total shares outstanding is 99.66%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Evogene's Insider Ownership is 0.00%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Evogene's Institutional Ownership is 0.85%.


Evogene Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

Evogene's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding=Float Shares/Total Shares Outstanding
=50.45/50.62
=99.66%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Evogene (Evogene) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Evogene Ltd (NAS:EVGN) » Definitions » Float Percentage Of Total Shares Outstanding
Traded in Other Exchanges
Address
13 Gad Feinstein Street, Park Rehovot, P.O. Box 4173, Ness Ziona, Rehovot, ISR, 7414002
Evogene Ltd is a computational biology company targeting to revolutionize product development for life-science based industries, including human health, agriculture, and industrial applications. The company established its technology, the Computational Predictive Biology (CPB) platform. The CPB platform is designed to computationally discover and develop life-science products based on microbes, small molecules and genetic elements as the core components for such products. It holds a number of subsidiaries utilizing the CPB platform, for the development of human microbiome-based therapeutics, medical cannabis, ag-biologicals, ag-chemicals, seed traits and ag-solutions for castor oil production. It generates maximum revenue from the Agriculture segment.